NXTC

0.438

6.31% 0.026

Dopo l'orario di chiusura: .44 0.002 +0.46%

Nextcure Inc (NXTC)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché NXTC Giù? Forum Previsione

Precedente Chiudi:

$0.412

Aprire:

$0.4305

Volume 24 ore:

55,615

Relative Volume:

0.38

Capitalizzazione di mercato:

$12.29M

Reddito:

Utile/perdita netta:

$-58.52M

Rapporto P/E:

-0.2096

EPS:

-2.09

Flusso di cassa netto:

$-45.03M

1 W Prestazione:

-1.79%

1M Prestazione:

+30.82%

6M Prestazione:

-66.56%

1 anno Prestazione:

-73.45%

Intervallo 1D:

$0.4205

$0.4499

Intervallo di 1 settimana:

$0.40

$0.4698

Portata 52W:

$0.224

$1.8199

Nextcure Inc Stock (NXTC) Company Profile

Nome

Nextcure Inc

Settore

Healthcare (1170)

Industria

Biotechnology (671)

Telefono

240-399-4900

Indirizzo

9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD

Dipendente

Cinguettio

@nextcureinc

Prossima data di guadagno

2025-03-07

Ultimi documenti SEC

NXTC's Discussions on Twitter

Confronta NXTC con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NXTC Nextcure Inc	0.438	12.51M	0	-58.52M	-45.03M	-2.09
ONC Beigene Ltd Adr	228.38	25.07B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	438.65	109.14B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.27	36.39M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	594.32	56.98B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	71.31	5.39B	0	-153.72M	-103.81M	-2.00

Nextcure Inc Stock (NXTC) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2022-11-04	Downgrade	Ladenburg Thalmann	Buy → Neutral
2022-03-01	Iniziato	Ladenburg Thalmann	Buy
2021-03-05	Aggiornamento	Truist	Hold → Buy
2021-01-15	Downgrade	BofA Securities	Neutral → Underperform
2020-07-16	Aggiornamento	The Benchmark Company	Hold → Buy
2020-07-13	Downgrade	ROTH Capital	Buy → Neutral
2020-07-13	Downgrade	SunTrust	Buy → Hold
2020-06-01	Downgrade	BofA/Merrill	Buy → Neutral
2020-06-01	Downgrade	The Benchmark Company	Buy → Hold
2020-05-26	Iniziato	JMP Securities	Mkt Outperform
2020-03-24	Iniziato	The Benchmark Company	Buy
2020-03-02	Iniziato	ROTH Capital	Buy
2020-01-13	Iniziato	SunTrust	Buy
2019-12-05	Iniziato	Needham	Buy
2019-11-26	Iniziato	BTIG Research	Buy
2019-07-09	Iniziato	BofA/Merrill	Buy
2019-06-03	Iniziato	Morgan Stanley	Overweight
2019-06-03	Iniziato	Piper Jaffray	Overweight

Mostra tutto

Nextcure Inc Borsa (NXTC) Ultime notizie

May 02, 2025

NextCure Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 02, 2025

NextCure Reports Q1 2025 Results and Strategic Progress - TipRanks

May 02, 2025

May 01, 2025

NextCure (NXTC) Advances LNCB74 Program in Phase 1 Study | NXTC Stock News - GuruFocus

May 01, 2025

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results - The Manila Times

May 01, 2025

NextCure, Inc. SEC 10-Q Report - TradingView

May 01, 2025

NextCure Expands Cancer Drug Trial to 13 Sites as Phase 1 ADC Study Hits Key Milestone - Stock Titan

May 01, 2025

Apr 28, 2025

NextCure Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView

Apr 28, 2025

Apr 26, 2025

Is Nextcure Inc’s -69.93% Fall This Year Is A Better Investing Opportunity? - Marketing Sentinel

Apr 26, 2025

Apr 24, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 24, 2025

Apr 11, 2025

It’s Worth A Gamble To Have A Position In Applied Therapeutics Inc (NASDAQ: APLT) At $0.32. - Marketing Sentinel

Apr 11, 2025

Apr 10, 2025

NextCure Updates Presentation on LNCB74 Clinical Trial - TipRanks

Apr 10, 2025

NextCure stock hits 52-week low at $0.3 amid sharp decline - Investing.com Australia

Apr 10, 2025

Apr 09, 2025

NextCure stock hits 52-week low at $0.3 amid sharp decline By Investing.com - Investing.com South Africa

Apr 09, 2025

12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

Apr 09, 2025

Apr 07, 2025

2seventy, TG, Springworks lead cancer index among Q1 market falls - BioWorld MedTech

Apr 07, 2025

Apr 04, 2025

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference - The Manila Times

Apr 04, 2025

Cancer Therapy Breakthrough? NextCure's Major Presentation at Needham Healthcare Conference - Stock Titan

Apr 04, 2025

Apr 03, 2025

CLASS ACTION UPDATE for PLAN, NXTC and BTU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire

Apr 03, 2025

Apr 01, 2025

NextCure stock plunges to 52-week low, hits $0.46 - Investing.com India

Apr 01, 2025

NextCure stock plunges to 52-week low, hits $0.46 By Investing.com - Investing.com Australia

Apr 01, 2025

Mar 25, 2025

NextCure stock hits 52-week low at $0.55 amid market challenges By Investing.com - Investing.com South Africa

Mar 25, 2025

NextCure stock hits 52-week low at $0.55 amid market challenges - Investing.com India

Mar 25, 2025

Mar 20, 2025

ROSEN, A LEADING LAW FIRM, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – NXTC - Business Wire

Mar 20, 2025

Mar 19, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Mar 19, 2025

Mar 18, 2025

H.C. Wainwright maintains Buy rating, $3 target on NextCure stock - Investing.com India

Mar 18, 2025

H.C. Wainwright maintains Buy rating, $3 target on NextCure stock By Investing.com - Investing.com South Africa

Mar 18, 2025

NextCure’s (NXTC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Mar 18, 2025

Mar 17, 2025

NextCure stock plunges to 52-week low at $0.66 amid market challenges - Investing.com Australia

Mar 17, 2025

Mar 13, 2025

NextCure (NXTC) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 13, 2025

Mar 10, 2025

NextCure Provides Business Update and Reports Full Year 2024 Financial Results - The Manila Times

Mar 07, 2025

Mar 06, 2025

NextCure, Inc. Completes First Cohort of Phase 1 Trial for LNCB74 and Plans for Backfill Cohorts - Nasdaq

Mar 06, 2025

Can NextCure's $68M Cash Support Its Cancer Drug Development Through 2026? - StockTitan

Mar 06, 2025